Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform

RegulatoryapprovedAdenoVerse PlatformPositive

AI Analysis

Summary

Precigen received FDA Platform Technology Designation for its AdenoVerse platform, which has the potential to accelerate development of current and future therapies built on this platform.

Outcome Details

FDA Platform Technology Designation granted for AdenoVerse Platform

Importance:6/10

Sentiment:

0.70

FDA designationplatform technologyregulatorygene therapy

Related Companies

$PGEN

Read the original article

Published by PR Newswire Biotech on September 21, 2026 11:00 AM

Read Original